文献速递儿科与产科急症重症综合管理与镇静镇痛

艾司氯胺酮用于择期剖宫产补充镇痛的疗效与安全性:一项随机临床试验

Efficacy and Safety of Esketamine for Supplemental Analgesia During Elective Cesarean Delivery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论择期剖宫产硬膜外麻醉下切皮前静脉给予亚麻醉剂量艾司氯胺酮0.25 mg/kg可产生一过性镇痛与镇静,不引起显著新生儿抑制,但精神症状和眼震常见且一过性。

这项多中心、双盲随机临床试验在5个医疗中心纳入600名18岁及以上、足月单胎、拟在硬膜外麻醉下择期剖宫产的女性,随机在切皮前静脉注射艾司氯胺酮0.25 mg/kg或安慰剂。主要终点为胎儿娩出后即刻的数字评定量表疼痛评分和Ramsay镇静评分:艾司氯胺酮组疼痛评分中位数0(IQR 0-1)低于安慰剂组0(IQR 0-2)(中位差0,95%CI 0-0,P=.001),但差异无临床重要性;Ramsay镇静评分艾司氯胺酮组4(IQR 3-4)高于安慰剂组2(IQR 2-2)(中位差2,95%CI 2-2,P<.001)。新生儿1分钟和5分钟Apgar评分两组无差异(1分钟中位差0,95%CI 0-0,P=.98;5分钟中位差0,95%CI 0-0,P=.27)。一过性神经或精神症状在艾司氯胺酮组更常见(97.7%[293/300] vs 4.7%[14/300],P<.001)。作者认为该人群的适应证和最佳剂量需进一步明确,研究应限于需要补充镇痛者。

要点

  • 择期剖宫产硬膜外麻醉下切皮前静脉注射艾司氯胺酮0.25 mg/kg,胎儿娩出后即刻疼痛评分中位数0(IQR 0-1) vs 安慰剂0(IQR 0-2),中位差0(95%CI 0-0,P=.001),但差异无临床重要性。
  • 艾司氯胺酮组Ramsay镇静评分中位数4(IQR 3-4)高于安慰剂组2(IQR 2-2),中位差2(95%CI 2-2,P<.001),镇静更深。
  • 新生儿1分钟Apgar评分中位差0(95%CI 0-0,P=.98)、5分钟中位差0(95%CI 0-0,P=.27),两组无差异,未诱导显著新生儿抑制。
  • 一过性神经或精神症状艾司氯胺酮组97.7%(293/300) vs 安慰剂组4.7%(14/300),P<.001,精神症状和眼震常见但一过性。
  • 作者认为该人群的适应证和最佳剂量需进一步明确,研究应限于需要补充镇痛者。

适用人群与场景

  • 18岁及以上、足月单胎妊娠、拟在硬膜外麻醉下择期剖宫产的女性;2021年9月18日至2022年9月20日在中国5个医疗中心纳入。

处置流程与药物剂量

  • 切皮前静脉注射艾司氯胺酮0.25 mg/kg或安慰剂(研究方案干预,非通用推荐)。

研究设计与关键结果

  • 多中心、双盲随机临床试验,5个医疗中心,600名女性(平均[SD]年龄30.7[4.3]岁)纳入并随机,全部纳入意向性治疗分析;干预为切皮前静脉注射艾司氯胺酮0.25 mg/kg或安慰剂。
  • 主要终点:胎儿娩出后即刻数字评定量表疼痛评分艾司氯胺酮组中位数0(IQR 0-1) vs 安慰剂组0(IQR 0-2),中位差0(95%CI 0-0,P=.001),差异无临床重要性(临床意义阈值为≥1.65分)。
  • 主要终点:Ramsay镇静评分艾司氯胺酮组中位数4(IQR 3-4) vs 安慰剂组2(IQR 2-2),中位差2(95%CI 2-2,P<.001),镇静更深(临床意义阈值为≥2分)。
  • 新生儿Apgar评分1分钟中位差0(95%CI 0-0,P=.98)、5分钟中位差0(95%CI 0-0,P=.27),两组无差异。
  • 一过性神经或精神症状艾司氯胺酮组97.7%(293/300) vs 安慰剂组4.7%(14/300),P<.001。

证据类型、等级与局限

  • 证据类型:多中心、双盲随机临床试验;试验注册号ClinicalTrials.gov NCT04548973。
  • 局限:作者指出该人群的适应证和最佳剂量需进一步明确,研究应限于需要补充镇痛者。

对床旁实践的改变

  • 作者认为该人群的适应证和最佳剂量需进一步明确,研究应限于需要补充镇痛者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Epidural anesthesia is a primary choice for cesarean delivery, but supplemental analgesics are often required to relieve pain during uterine traction.

OBJECTIVE: To investigate the sedative and analgesic effects of intravenous esketamine administered before childbirth via cesarean delivery with the patient under epidural anesthesia.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind randomized clinical trial assessed 903 women 18 years or older who had full-term single pregnancy and were scheduled for elective cesarean delivery with epidural anesthesia in 5 medical centers in China from September 18, 2021, to September 20, 2022.

INTERVENTION: Patients were randomized to receive intravenous injection of 0.25 mg/kg of esketamine or placebo before incision.

MAIN OUTCOMES AND MEASURES: The coprimary outcomes included scores on the numeric rating scale of pain (an 11-point scale, with 0 indicating no pain and 10 indicating the worst pain; a difference of ≥1.65 points was clinically meaningful) and Ramsay Sedation Scale (a 6-point scale, with 1 indicating restlessness and 6 indicating deep sleep without response; a difference of ≥2 points was clinically meaningful) immediately after fetal delivery. Secondary outcomes included neonatal Apgar score assessed at 1 and 5 minutes after birth.

RESULTS: A total of 600 women (mean [SD] age, 30.7 [4.3] years) were enrolled and randomized; all were included in the intention-to-treat analysis. Immediately after fetal delivery, the score on the numeric rating scale of pain was lower with esketamine (median [IQR], 0 [0-1]) than with placebo (median [IQR], 0 [0-2]; median difference, 0; 95% CI, 0-0; P = .001), but the difference was not clinically important. The Ramsay Sedation Scale scores were higher (sedation deeper) with esketamine (median [IQR], 4 [3-4]) than with placebo (median [IQR], 2 [2-2]; median difference, 2; 95% CI, 2-2; P < .001). The neonatal Apgar scores did not differ between the 2 groups at 1 minute (median difference, 0; 95% CI, 0-0; P = .98) and at 5 minutes (median difference, 0; 95% CI, 0-0; P = .27). Transient neurologic or mental symptoms were more common in patients given esketamine (97.7% [293 of 300]) than in those given placebo (4.7% [14 of 300]; P < .001).

CONCLUSIONS AND RELEVANCE: For women undergoing cesarean delivery under epidural anesthesia, a subanesthetic dose of esketamine administered before incision produced transient analgesia and sedation but did not induce significant neonatal depression. Mental symptoms and nystagmus were common but transient. Indications and the optimal dose of esketamine in this patient population need further clarification, but study should be limited to those who require supplemental analgesia.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04548973.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Xu LL, Wang C, Deng CM, et al. Efficacy and Safety of Esketamine for Supplemental Analgesia During Elective Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37083664. doi:10.1001/jamanetworkopen.2023.9321

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。